Fund+, an investment firm focused on European life sciences companies, has appointed Luc Debruyne and Gérard Lamarche to the Board.
Luc Debruyne was president of global vaccines and member of the Corporate Executive Team at GlaxoSmithKline.
Gérard Lamarche is a director and member of the Standing Committee of Groupe Bruxelles Lambert.
Chris Buyse, managing partner and executive board member of Fund+, said: “We are delighted to welcome Luc Debruyne and Gérard Lamarche to the Board. Luc Debruyne brings outstanding scientific and commercialisation experience from GSK, where he led the global vaccines business; and a wealth of international expertise having worked across Europe and managed businesses globally including significant focus and experience in the US. Gérard Lamarche will leverage his track record of successful transactions and brings an invaluable perspective to the Board following an impressive track record of strategic roles at well-established industrial companies."